Sei Investments Co. Buys 10,908 Shares of iRadimed Corporation $IRMD

Sei Investments Co. lifted its stake in shares of iRadimed Corporation (NASDAQ:IRMD) by 17.2% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 74,304 shares of the medical equipment provider’s stock after purchasing an additional 10,908 shares during the quarter. Sei Investments Co. owned 0.58% of iRadimed worth $7,153,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of IRMD. Royal Bank of Canada lifted its position in iRadimed by 14.7% during the first quarter. Royal Bank of Canada now owns 25,782 shares of the medical equipment provider’s stock worth $1,354,000 after purchasing an additional 3,307 shares during the period. AQR Capital Management LLC increased its holdings in iRadimed by 7.5% in the 1st quarter. AQR Capital Management LLC now owns 15,829 shares of the medical equipment provider’s stock valued at $831,000 after buying an additional 1,108 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in iRadimed by 5.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,811 shares of the medical equipment provider’s stock valued at $252,000 after buying an additional 234 shares during the period. Jones Financial Companies Lllp raised its position in shares of iRadimed by 8,568.5% in the 1st quarter. Jones Financial Companies Lllp now owns 11,269 shares of the medical equipment provider’s stock valued at $591,000 after buying an additional 11,139 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its position in shares of iRadimed by 1.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 169,387 shares of the medical equipment provider’s stock valued at $8,889,000 after buying an additional 1,821 shares in the last quarter. Institutional investors own 92.34% of the company’s stock.

Trending Headlines about iRadimed

Here are the key news stories impacting iRadimed this week:

• Positive Sentiment: Earnings exceeded expectations. iRadimed reported second-quarter non-GAAP diluted EPS of $0.46, above the $0.42 consensus estimate; GAAP diluted EPS was $0.41. The company also reported a 24.48% return on equity and a 27.36% net margin. IRADIMED Corporation Reports Second Quarter 2026 Financial Results
• Positive Sentiment: 2026 EPS guidance is above analyst expectations. Full-year EPS guidance of $2.09-$2.24 compares with the $1.96 consensus estimate. Third-quarter EPS guidance of $0.54-$0.59 also exceeds the $0.53 consensus. IRADIMED Corporation Q2 2026 Earnings Call Transcript
• Positive Sentiment: iRadimed declared a regular quarterly dividend of $0.20 per share, providing a direct shareholder return. IRADIMED Corporation Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Revenue guidance is broadly in line with expectations. Third-quarter revenue guidance of $23.0-$24.5 million brackets the $23.7 million consensus, while full-year guidance of $91-$96 million is close to the $91.2 million estimate.
• Negative Sentiment: Revenue growth was weak. Second-quarter revenue reached $20.5 million, up only $0.1 million, or 0.5%, from the prior-year period. That modest growth may have tempered the positive impact of the EPS beat, particularly with shares trading at a trailing price-to-earnings ratio near 50.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded shares of iRadimed from a “buy (b)” rating to a “buy (b-)” rating in a report on Wednesday, May 20th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $120.00.

Insider Activity

In related news, CEO Roger E. Susi sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $90.60, for a total transaction of $226,500.00. Following the completion of the transaction, the chief executive officer directly owned 2,162,500 shares in the company, valued at $195,922,500. This represents a 0.12% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 17,500 shares of company stock worth $1,515,065. Insiders own 34.60% of the company’s stock.

iRadimed Price Performance

Shares of IRMD stock opened at $90.86 on Monday. iRadimed Corporation has a twelve month low of $57.83 and a twelve month high of $107.90. The company has a market cap of $1.16 billion, a P/E ratio of 50.76 and a beta of 0.90. The business has a fifty day simple moving average of $94.54 and a 200 day simple moving average of $95.68.

iRadimed (NASDAQ:IRMD) last released its quarterly earnings data on Friday, July 31st. The medical equipment provider reported $0.46 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.02. The business had revenue of $20.47 million for the quarter, compared to analyst estimates of $20.35 million. iRadimed had a return on equity of 23.73% and a net margin of 26.70%.iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. As a group, equities research analysts anticipate that iRadimed Corporation will post 1.52 earnings per share for the current fiscal year.

iRadimed Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, August 28th. Investors of record on Friday, August 14th will be issued a dividend of $0.20 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $0.80 annualized dividend and a dividend yield of 0.9%. iRadimed’s payout ratio is 44.69%.

iRadimed Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.